Extended Data Table 2 Overall safety summary of sac-TMT 5 mg/kg every 2 weeks in NSCLC

From: Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials